Literature DB >> 24484462

Risk and benefit of statins in stroke secondary prevention.

Patrice Laloux1.   

Abstract

Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24484462     DOI: 10.2174/157016111106140128113121

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  3 in total

1.  Statin use after intracerebral hemorrhage: a 10-year nationwide cohort study.

Authors:  Shu-Yu Tai; Feng-Cheng Lin; Chung-Yin Lee; Chai-Jan Chang; Ming-Tsang Wu; Chen-Yu Chien
Journal:  Brain Behav       Date:  2016-05-13       Impact factor: 2.708

2.  Quality of life and depression 3 months after intracerebral hemorrhage.

Authors:  Hanne Sallinen; Tiina Sairanen; Daniel Strbian
Journal:  Brain Behav       Date:  2019-03-24       Impact factor: 2.708

3.  16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Authors:  Hannah Cohen; Maria J Cuadrado; Doruk Erkan; Ali Duarte-Garcia; David A Isenberg; Jason S Knight; Thomas L Ortel; Anisur Rahman; Jane E Salmon; Maria G Tektonidou; David J Williams; Rohan Willis; Scott C Woller; Danieli Andrade
Journal:  Lupus       Date:  2020-10       Impact factor: 2.911

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.